Ad
GLYC - GlycoMimetics Stock Trading
About | GlycoMimetics Inc. (NASDAQ:GLYC)
None
Quote | GlycoMimetics Inc. (NASDAQ:GLYC)
| Last: | $1.72 |
|---|---|
| Change Percent: | 0.61% |
| Open: | $1.63 |
| Close: | $1.72 |
| High: | $1.74 |
| Low: | $1.6 |
| Volume: | 113,468 |
| Last Trade Date Time: | 12/01/2023 03:00:00 am |
News | GlycoMimetics Inc. (NASDAQ:GLYC)
-
2023-11-27 18:51:52 ET Summary GlycoMimetics' uproleselan shows promise in AML, but Phase 3 trial changes introduce data interpretation and regulatory complexities. GlycoMimetics faces increased R&D and G&A expenses; financial health is stable short term but precarious lon...
-
GlycoMimetics, Inc. (Nasdaq: GLYC) today announced that Harout Semerjian, Chief Executive Officer, will participate in a fireside chat at the Jefferies London Healthcare Conference in London, UK on Thursday, November 16, 2023 at 1:30 p.m. GMT/8:30 a.m. ET. A live webcast of the fireside chat ...
Message Board Posts | GlycoMimetics Inc. (NASDAQ:GLYC)
| Subject | By | Source | When |
|---|---|---|---|
| whytestocks: $GLYC News Article - GlycoMimetics to Report Fourth Quarter and 2022 Full Year Financia | whytestocks | investorshangout | 03/16/2023 12:50:50 PM |
| Dilution. | willlbone | investorshub | 02/15/2023 8:28:30 PM |
| Reversal | INFINITI | investorshub | 02/15/2023 4:04:52 PM |
| Picked up a few heavy racks of shares | TechandBio | investorshub | 01/04/2023 12:37:49 AM |
| whytestocks: $GLYC News Article - Best Penny Stocks To Buy Now? 4 Stocks Under $4 To Watch | whytestocks | investorshangout | 12/28/2022 6:25:45 PM |
News, Short Squeeze, Breakout and More Instantly...
Ad
-
GlycoMimetics, Inc. (Nasdaq: GLYC) today announced that Harout Semerjian, Chief Executive Officer, will participate in a fireside chat at the Jefferies London Healthcare Conference in London, UK on Thursday, November 16, 2023 at 1:30 p.m. GMT/8:30 a.m. ET. A live webcast of the fireside chat ...
-
HST Global Inc (HSTC) is expected to report for quarter end 2023-09-30 Air China Ltd ADR - Level I (AIRYY) is expected to report for Q3 2023 GrafTech International Ltd. (EAF) is expected to report $-0.05 for Q3 2023 Cardinal Health Inc. (CAH) is expected to report $1.4 for Q1 2024 ...
-
Topline results from pivotal Phase 3 study of uproleselan in relapsed/refractory (R/R) Acute Myeloid Leukemia (AML) on track to be reported by end of Q2 2024 NDA filing for uproleselan anticipated by end of 2024 pending outcome of R/R AML pivotal study Initial results for GMI-1687 Phase 1...